Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$37.06 -0.9%	$39.66	$11.20 ▼ $72.98	$8.31B	1.37	13.93 million shs	17.49 million shs
LFMD LifeMD	$6.00 -1.6%	$5.78	$3.99 ▼ $12.88	$271.96M	1.5	801,014 shs	797,438 shs
LLY Eli Lilly and Company	$852.35 -1.5%	$839.56	$711.40 ▼ $972.53	$808.17B	0.34	3.15 million shs	2.67 million shs
NVO Novo Nordisk A/S	$73.57 -2.3%	$83.01	$73.20 ▼ $148.15	$330.15B	0.42	5.45 million shs	8.87 million shs
PFE Pfizer	$25.56 -2.2%	$26.14	$24.48 ▼ $31.54	$144.96B	0.61	36.71 million shs	47.48 million shs
TDOC Teladoc Health	$8.65 -1.9%	$10.39	$6.76 ▼ $15.43	$1.50B	1.27	6.05 million shs	4.20 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	-0.82%	+17.81%	-24.51%	+31.65%	+127.22%
LFMD LifeMD	-1.64%	+6.19%	+9.89%	+22.20%	-43.40%
LLY Eli Lilly and Company	-1.57%	+3.73%	-2.49%	+7.12%	+10.31%
NVO Novo Nordisk A/S	-2.30%	-9.12%	-16.46%	-15.79%	-42.99%
PFE Pfizer	-2.19%	-2.84%	-2.88%	-4.41%	-6.82%
TDOC Teladoc Health	-2.32%	+3.03%	-24.88%	-6.59%	-42.64%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HIMS Hims & Hers Health	2.4299 of 5 stars	2.1	2.0	0.0	0.0	2.8	3.3	1.9
LFMD LifeMD	2.2675 of 5 stars	3.5	1.0	0.0	0.0	3.3	1.7	0.6
LLY Eli Lilly and Company	4.6121 of 5 stars	2.4	3.0	3.3	4.0	2.9	2.5	1.9
NVO Novo Nordisk A/S	4.688 of 5 stars	4.4	4.0	1.7	0.0	1.9	0.0	4.4
PFE Pfizer	4.9138 of 5 stars	2.3	3.0	4.2	4.2	2.8	3.3	3.1
TDOC Teladoc Health	3.2 of 5 stars	4.2	2.0	0.0	0.0	1.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HIMS Hims & Hers Health	2.27	Hold	$37.31	0.67% Upside
LFMD LifeMD	3.00	Buy	$11.43	90.48% Upside
LLY Eli Lilly and Company	2.85	Moderate Buy	$1,009.72	18.46% Upside
NVO Novo Nordisk A/S	2.80	Moderate Buy	$145.25	97.43% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	24.89% Upside
TDOC Teladoc Health	2.39	Hold	$11.26	30.23% Upside

Current Analyst Ratings Breakdown

Latest HIMS, PFE, LLY, NVO, TDOC, and LFMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$21.00 ➝ $22.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	NVO Novo Nordisk A/S	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/12/2025	LFMD LifeMD	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $14.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	LFMD LifeMD	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/11/2025	LFMD LifeMD	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$15.00 ➝ $15.00
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/6/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1,146.00
3/6/2025	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform	$21.00 ➝ $21.00
3/6/2025	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell	$27.00 ➝ $27.00

(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HIMS Hims & Hers Health	$1.48B	5.58	N/A	N/A	$1.61 per share	23.02
LFMD LifeMD	$212.45M	1.26	N/A	N/A	$0.15 per share	40.00
LLY Eli Lilly and Company	$45.04B	17.94	$13.90 per share	61.34	$15.05 per share	56.63
NVO Novo Nordisk A/S	$290.40B	1.14	$3.41 per share	21.57	$4.64 per share	15.86
PFE Pfizer	$63.63B	2.28	$4.01 per share	6.38	$15.81 per share	1.62
TDOC Teladoc Health	$2.57B	0.58	$0.55 per share	15.64	$14.05 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HIMS Hims & Hers Health	-$23.55M	$0.54	84.23	71.27	N/A	8.19%	10.97%	8.29%	5/5/2025 (Estimated)
LFMD LifeMD	-$20.60M	-$0.54	N/A	50.00	N/A	-12.06%	N/A	-36.34%	5/6/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	72.79	27.39	1.40	23.51%	85.24%	16.19%	4/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.29	22.36	15.79	0.90	34.81%	84.68%	26.29%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.13	8.44	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
TDOC Teladoc Health	-$220.37M	-$5.88	N/A	N/A	N/A	-37.91%	-10.06%	-4.86%	4/24/2025 (Estimated)

Latest HIMS, PFE, LLY, NVO, TDOC, and LFMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/10/2025	Q4 2024	LFMD LifeMD	-$0.04	-$0.02	+$0.02	-$0.02	$57.43 million	$64.26 million
2/26/2025	Q4 2024	TDOC Teladoc Health	-$0.21	-$0.28	-$0.07	-$0.28	$639.44 million	$640.49 million
2/24/2025	Q4 2024	HIMS Hims & Hers Health	$0.09	$0.11	+$0.02	$0.11	$494.56 million	$481.14 million
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/5/2025	Q4 2024	NVO Novo Nordisk A/S	$0.88	$0.91	+$0.03	$0.91	N/A	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LFMD LifeMD	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.70%	+15.21%	51.24%	11 Years
NVO Novo Nordisk A/S	$1.57	2.13%	+25.26%	47.72%	N/A
PFE Pfizer	$1.72	6.73%	+2.50%	121.99%	16 Years
TDOC Teladoc Health	N/A	N/A	N/A	N/A	N/A

Latest HIMS, PFE, LLY, NVO, TDOC, and LFMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	NVO Novo Nordisk A/S	semi-annual	$0.7874	1.2%	3/31/2025	3/31/2025	4/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HIMS Hims & Hers Health	N/A	2.14	1.82
LFMD LifeMD	N/A	0.83	0.78
LLY Eli Lilly and Company	2.00	1.15	0.97
NVO Novo Nordisk A/S	0.62	0.74	0.55
PFE Pfizer	0.63	1.00	0.73
TDOC Teladoc Health	0.66	1.73	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HIMS Hims & Hers Health	63.52%
LFMD LifeMD	35.52%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
TDOC Teladoc Health	76.82%

Insider Ownership

Company	Insider Ownership
HIMS Hims & Hers Health	17.71%
LFMD LifeMD	15.97%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%
TDOC Teladoc Health	0.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HIMS Hims & Hers Health	650	222.17 million	179.79 million	Optionable
LFMD LifeMD	230	44.58 million	36.40 million	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
NVO Novo Nordisk A/S	54,400	4.49 billion	4.48 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
TDOC Teladoc Health	5,100	173.67 million	170.53 million	Optionable

HIMS, PFE, LLY, NVO, TDOC, and LFMD Headlines

Recent News About These Companies

Teladoc Health Inc.

March 24 at 12:14 PM | wsj.com

56,131 Shares in Teladoc Health, Inc. (NYSE:TDOC) Bought by Proficio Capital Partners LLC

March 24 at 3:15 AM | marketbeat.com

Vinva Investment Management Ltd Takes Position in Teladoc Health, Inc. (NYSE:TDOC)

March 23 at 4:48 AM | marketbeat.com

Insider Selling: Teladoc Health, Inc. (NYSE:TDOC) Insider Sells 11,011 Shares of Stock

March 22, 2025 | marketbeat.com

Adam C. Vandervoort Sells 11,011 Shares of Teladoc Health, Inc. (NYSE:TDOC) Stock

March 22, 2025 | insidertrades.com

Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) PT at $11.26

March 21, 2025 | americanbankingnews.com

Teladoc (TDOC) Exceeds Market Returns: Some Facts to Consider

March 19, 2025 | zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

March 19, 2025 | accessnewswire.com

Charles Schwab Investment Management Inc. Increases Holdings in Teladoc Health, Inc. (NYSE:TDOC)

March 19, 2025 | marketbeat.com

Teladoc Health, Inc. (NYSE:TDOC) Shares Sold by Bank of New York Mellon Corp

March 18, 2025 | marketbeat.com

Teladoc Health, Inc. (NYSE:TDOC) Given Average Rating of "Hold" by Brokerages

March 18, 2025 | marketbeat.com

Teladoc Health Q1 Preview: Analyst Says Strategic Direction Is Good, But There's 'More Work To Be Done'

March 17, 2025 | benzinga.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

March 17, 2025 | prnewswire.com

J.P. Morgan Keeps Their Hold Rating on Teladoc (TDOC)

March 17, 2025 | markets.businessinsider.com

Does Teladoc's $65 Million Acquisition of Catapult Health Make the Stock a Buy?

March 17, 2025 | fool.com

Teladoc Health Q1 EPS Estimate Reduced by Zacks Research

March 17, 2025 | americanbankingnews.com

Zacks Research Reduces Earnings Estimates for Teladoc Health

March 17, 2025 | marketbeat.com

Teladoc Health, Inc. (NYSE:TDOC) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

March 16, 2025 | marketbeat.com

Zacks Research Predicts Teladoc Health FY2027 Earnings

March 16, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

March 15, 2025 | accessnewswire.com

Zacks Research Comments on Teladoc Health FY2027 Earnings

March 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Intel Foundry’s Moment of Truth: Will 18A Deliver?
By Jeffrey Neal Johnson | March 6, 2025
View Intel Foundry’s Moment of Truth: Will 18A Deliver?
Missed the Hims & Hers Rally? Clover Health Could Be Next
By Gabriel Osorio-Mazilli | March 5, 2025
View Missed the Hims & Hers Rally? Clover Health Could Be Next
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
By Sarah Horvath | March 3, 2025
View These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
By Thomas Hughes | February 27, 2025
View 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year

HIMS, PFE, LLY, NVO, TDOC, and LFMD Company Descriptions

Hims & Hers Health NYSE:HIMS

$37.06 -0.35 (-0.94%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$36.94 -0.12 (-0.32%)

As of 03/25/2025 07:59 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

LifeMD NASDAQ:LFMD

$6.00 -0.10 (-1.64%)

Closing price 03/25/2025 04:00 PM Eastern

Extended Trading

$6.03 +0.03 (+0.52%)

As of 03/25/2025 07:59 PM Eastern

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Eli Lilly and Company NYSE:LLY

$852.35 -12.55 (-1.45%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$852.13 -0.22 (-0.03%)

As of 03/25/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$73.57 -1.76 (-2.34%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$73.68 +0.11 (+0.14%)

As of 03/25/2025 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$25.56 -0.58 (-2.22%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$25.63 +0.07 (+0.27%)

As of 03/25/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Teladoc Health NYSE:TDOC

$8.65 -0.17 (-1.93%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$8.65 0.00 (0.00%)

As of 03/25/2025 07:58 PM Eastern

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIMS, PFE, LLY, NVO, TDOC, and LFMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIMS, PFE, LLY, NVO, TDOC, and LFMD Earnings

Compare Dividends

Latest HIMS, PFE, LLY, NVO, TDOC, and LFMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIMS, PFE, LLY, NVO, TDOC, and LFMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIMS, PFE, LLY, NVO, TDOC, and LFMD Company Descriptions

Hims & Hers Health NYSE:HIMS

LifeMD NASDAQ:LFMD

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

Teladoc Health NYSE:TDOC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools